
Opinion|Videos|April 14, 2025
Exploring Updates From KEYNOTE-799 at ELCC 2025
Panelists discuss how KEYNOTE-799 provides updated data on safety, toxicity, positive response rates, and median survival rates for both squamous and nonsquamous non–small cell lung cancer treatments.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5
































